Fortrea Holdings Inc. is a provider of clinical development and patient access solutions to the life sciences industry. It provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea Holdings Inc. is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $2.70B |
| Net Income (Most Recent Fiscal Year) | $-328.50M |
| PE Ratio (Current Year Earnings Estimate) | 29.33 |
| PE Ratio (Trailing 12 Months) | 28.59 |
| PEG Ratio (Long Term Growth Estimate) | 0.68 |
| Price to Sales Ratio (Trailing 12 Months) | 0.49 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.28 |
| Pre-Tax Margin (Trailing 12 Months) | -37.04% |
| Net Margin (Trailing 12 Months) | -36.77% |
| Return on Equity (Trailing 12 Months) | 5.64% |
| Return on Assets (Trailing 12 Months) | 1.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.00 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.81 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.19 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $0.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-11.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 92.40M |
| Free Float | 92.05M |
| Market Capitalization | $1.35B |
| Average Volume (Last 20 Days) | 1.23M |
| Beta (Past 60 Months) | 1.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.38% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |